Abstract
Surfactant associated protein-A (SP-A) is the most abundant pulmonary surfactant protein and belongs to the family of innate host defense proteins termed collectins. Besides pulmonary host defense, SP-A is also involved in the formation of pulmonary surfactant, as it is essential for the structure of tubular myelin. The human SP-A gene locus includes two functional genes, SFTPA1 and SFTPA2 which are expressed independently, and a pseudo gene. The largest amount of SP-A1 proteins assemble to larger molecular complexes, whereas SP-A2 forms mainly dimers and trimers. SPA polymorphisms play a role in respiratory distress syndrome, allergic bronchopulmonary aspergillosis and idiopathic pulmonary fibrosis. The levels of SP-A are decreased in the lungs of patients with cystic fibrosis, respiratory distress syndrome and further chronic lung diseases. Future areas for clinical research include disease specific SP-A expression pattern and their functional consequences, the differential roles of SP-A1 and SP-A2 in human lung diseases, and therapeutical approaches to correct altered SP-A levels.
Keywords: surfactant protein A, innate immunity, polymorphisms, lung diseases
Current Medicinal Chemistry
Title: Surfactant Protein A - From Genes to Human Lung Diseases
Volume: 13 Issue: 27
Author(s): S. Heinrich, D. Hartl and M. Griese
Affiliation:
Keywords: surfactant protein A, innate immunity, polymorphisms, lung diseases
Abstract: Surfactant associated protein-A (SP-A) is the most abundant pulmonary surfactant protein and belongs to the family of innate host defense proteins termed collectins. Besides pulmonary host defense, SP-A is also involved in the formation of pulmonary surfactant, as it is essential for the structure of tubular myelin. The human SP-A gene locus includes two functional genes, SFTPA1 and SFTPA2 which are expressed independently, and a pseudo gene. The largest amount of SP-A1 proteins assemble to larger molecular complexes, whereas SP-A2 forms mainly dimers and trimers. SPA polymorphisms play a role in respiratory distress syndrome, allergic bronchopulmonary aspergillosis and idiopathic pulmonary fibrosis. The levels of SP-A are decreased in the lungs of patients with cystic fibrosis, respiratory distress syndrome and further chronic lung diseases. Future areas for clinical research include disease specific SP-A expression pattern and their functional consequences, the differential roles of SP-A1 and SP-A2 in human lung diseases, and therapeutical approaches to correct altered SP-A levels.
Export Options
About this article
Cite this article as:
Heinrich S., Hartl D. and Griese M., Surfactant Protein A - From Genes to Human Lung Diseases, Current Medicinal Chemistry 2006; 13 (27) . https://dx.doi.org/10.2174/092986706778773112
DOI https://dx.doi.org/10.2174/092986706778773112 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action
Current Drug Targets Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Nano-Tetrandrine Efficiently Inhibits the Proliferation and Induces the Apoptosis of Hep2 Cells through a Mitochondrial Signaling Pathway
Current Signal Transduction Therapy Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms
Current Drug Metabolism Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Current Cancer Therapy Reviews The Influence of Traumatic Lumbar Puncture (TLP) on Outcome of Pediatric Patients
Current Pediatric Reviews Aptamers in Targeted Nanotherapy
Current Topics in Medicinal Chemistry EDITORIAL [Hot Topic: Modulation of the Immune System by Ionizing Irradiation and Chemotherapeutic Agents - Contribution of Immune Activation and Blocking of Immune Suppression to Cancer Therapy Success (Guest Editor: Udo S. Gaipl)]
Current Medicinal Chemistry Effect of Pinocembrin Isolated from Boesenbergia pandurata on Xenobiotic-Metabolizing Enzymes in Rat Liver
Drug Metabolism Letters Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials A Validated HPLC-PDA Method for the Analysis of Ursolic Acid Content in Poly(lactic acid) Nanoparticles
Current Chromatography Cancer Prevention with Green Tea Polyphenols for the General Population, and for Patients Following Cancer Treatment
Current Cancer Therapy Reviews Methodological Issues of Clinical Research with EGFR Inhibitors
Current Cancer Therapy Reviews Proteomics Using Mammospheres as a Model System to Identify Proteins Deregulated in Breast Cancer Stem Cells
Current Molecular Medicine Segmentation and Classification of Lung Cancer: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In Silico Prediction of P-glycoprotein Binding: Insights from Molecular Docking Studies
Current Medicinal Chemistry